|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
This Dallas Morning News editorial explains why giving the government the power to negotiate drug prices in the Medicare drug benefit is a bad ideafor the government and for the industry.
Giving the feds the power to negotiate drug prices for seniors would effectively cede control of the pharmaceutical industry to Washington. While the government negotiates drug prices for Medicaid patients and veterans, the enormous Medicare portfolio of 39 million beneficiaries would give the bureaucracy a veto over drug companies.
|home spotlight commentary research events news about contact links archives|